Advertisement

 

 

In silico design of Mycobacterium tuberculosis epitope ensemble vaccines.

In silico design of Mycobacterium tuberculosis epitope ensemble vaccines.
Author Information (click to view)

Shah P, Mistry J, Reche PA, Gatherer D, Flower DR,


Shah P, Mistry J, Reche PA, Gatherer D, Flower DR, (click to view)

Shah P, Mistry J, Reche PA, Gatherer D, Flower DR,

Advertisement

Molecular immunology 2018 03 1997() 56-62 pii 10.1016/j.molimm.2018.03.007

Abstract

Effective control of Mycobacterium tuberculosis is a global necessity. In 2015, tuberculosis (TB) caused more deaths than HIV. Considering the increasing prevalence of multi-drug resistant forms of M. tuberculosis, the need for effective TB vaccines becomes imperative. Currently, the only licensed TB vaccine is Bacillus Calmette-Guérin (BCG). Yet, BCG has many drawbacks limiting its efficacy and applicability. We applied advanced computational procedures to derive a universal TB vaccine and one targeting East Africa. Our approach selects an optimal set of highly conserved, experimentally validated epitopes, with high projected population coverage (PPC). Through rigorous data analysis, five different potential vaccine combinations were selected each with PPC above 80% for East Africa and above 90% for the World. Two potential vaccines only contained CD8+ epitopes, while the others included both CD4+ and CD8+ epitopes. Our prime vaccine candidate was a putative seven-epitope ensemble comprising: SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, AAHKGLMNIALAISA, FPAGGSTGSL, MLLAVTVSL, QSSFYSDW and KMRCGAPRY, with a 97.4% global PPC and a 92.7% East African PPC.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × 3 =

[ HIDE/SHOW ]